mazindol has been researched along with Dyskinesia, Drug-Induced in 4 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although L-DOPA treatment provides the most effective symptomatic relief for PD it does not prevent the progression of the disease, and its long-term use is associated with the onset of dyskinesia." | 1.31 | GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets. ( Cannizzaro, C; Costa, S; Iravani, MM; Jackson, MJ; Jenner, P; Pearce, RK; Tel, BC, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tel, BC | 2 |
| Zeng, BY | 1 |
| Cannizzaro, C | 2 |
| Pearce, RK | 2 |
| Rose, S | 1 |
| Jenner, P | 2 |
| Lundblad, M | 1 |
| Picconi, B | 1 |
| Lindgren, H | 1 |
| Cenci, MA | 1 |
| Henry, B | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 1 |
| Iravani, MM | 1 |
| Costa, S | 1 |
| Jackson, MJ | 1 |
4 other studies available for mazindol and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Dr | 2002 |
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mazindol | 2004 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, An | 1998 |
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Topics: Animals; Antiparkinson Agents; Body Weight; Callithrix; Corpus Striatum; Disease Models, Animal; Dop | 2001 |